(Total Views: 662)
Posted On: 12/09/2022 5:28:37 PM
Post# of 148878
Tough week for me with the CC. I can't keep doing this for 2 more years!
Sorry, but we need partnerships and new trials. Redefining all the old data and getting better business model and better graphs, et al is not what Leronlimab is about. There is only one job here, that's to get Leronlimab on the shelf. And even that doesn't guarantee money if the market is gone by the time we do it.
A whole year without one new trial, come on management, the hold is on HIV, not NASH, not mTNBC or any Breast Cancer. The 350 NASH was the end of last year, one would think the third trial would already be going. Find a partner and start a trial or find a buyout. I'm not happy as an investor. 350 million shares and all we got was a poster board.
I
s it just me, remember Brazil, we got 26 critical patients, so what are going for now, a real good academic NASH trial where we get 26 patients and Pfizer gets 1500?
We can not do this alone, the TOTAL focus now should be real partnerships with BP.
Sorry, but we need partnerships and new trials. Redefining all the old data and getting better business model and better graphs, et al is not what Leronlimab is about. There is only one job here, that's to get Leronlimab on the shelf. And even that doesn't guarantee money if the market is gone by the time we do it.
A whole year without one new trial, come on management, the hold is on HIV, not NASH, not mTNBC or any Breast Cancer. The 350 NASH was the end of last year, one would think the third trial would already be going. Find a partner and start a trial or find a buyout. I'm not happy as an investor. 350 million shares and all we got was a poster board.
I
s it just me, remember Brazil, we got 26 critical patients, so what are going for now, a real good academic NASH trial where we get 26 patients and Pfizer gets 1500?
We can not do this alone, the TOTAL focus now should be real partnerships with BP.
(17)
(0)Scroll down for more posts ▼
